Novavax Inc. (NVAX) Given a $12.00 Price Target by FBR & Co Analysts
Novavax Inc. (NASDAQ:NVAX) has been given a $12.00 price target by analysts at FBR & Co in a research report issued to clients and investors on Friday. The firm presently has a a “buy” rating on the biopharmaceutical company’s stock.
A number of other equities research analysts have also commented on NVAX. Vetr raised Novavax from a “buy” rating to a “strong-buy” rating and set a $8.35 price target on the stock in a research report on Tuesday, July 19th. Wedbush reissued an “outperform” rating and issued a $14.00 target price on shares of Novavax in a research report on Wednesday, July 27th. Citigroup Inc. lifted their target price on Novavax from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, July 28th. Zacks Investment Research lowered Novavax from a “hold” rating to a “sell” rating in a research report on Wednesday, August 10th. Finally, Chardan Capital reissued a “hold” rating and issued a $5.75 target price on shares of Novavax in a research report on Sunday, August 14th. Seven analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. Novavax currently has an average rating of “Hold” and a consensus price target of $7.01.
Novavax (NASDAQ:NVAX) opened at 1.35 on Friday. The stock’s 50 day moving average price is $1.68 and its 200-day moving average price is $5.18. Novavax has a one year low of $1.16 and a one year high of $9.23. The firm’s market capitalization is $366.11 million.
Novavax (NASDAQ:NVAX) last released its quarterly earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.26) by $0.02. The company had revenue of $3.20 million for the quarter, compared to analyst estimates of $4.02 million. Novavax had a negative return on equity of 189.14% and a negative net margin of 1,908.41%. Novavax’s revenue was down 50.8% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.12) earnings per share. On average, equities research analysts expect that Novavax will post ($1.05) EPS for the current fiscal year.
In other Novavax news, Director Michael A. Mcmanus, Jr. bought 30,000 shares of Novavax stock in a transaction dated Wednesday, September 21st. The stock was bought at an average cost of $1.61 per share, for a total transaction of $48,300.00. Following the purchase, the director now owns 247,590 shares of the company’s stock, valued at approximately $398,619.90. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP John Trizzino bought 46,000 shares of Novavax stock in a transaction dated Thursday, September 22nd. The shares were acquired at an average price of $2.17 per share, with a total value of $99,820.00. Following the completion of the purchase, the senior vice president now directly owns 85,564 shares in the company, valued at approximately $185,673.88. The disclosure for this purchase can be found here. 3.50% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently modified their holdings of NVAX. Coldstream Capital Management Inc. increased its position in shares of Novavax by 17.5% in the second quarter. Coldstream Capital Management Inc. now owns 13,805 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 2,055 shares in the last quarter. Principal Financial Group Inc. increased its position in shares of Novavax by 1.1% in the third quarter. Principal Financial Group Inc. now owns 48,096 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 536 shares in the last quarter. Compagnie Lombard Odier SCmA acquired a new position in shares of Novavax during the second quarter valued at approximately $102,000. Veritable L.P. acquired a new position in shares of Novavax during the second quarter valued at approximately $102,000. Finally, BlackRock Inc. increased its position in shares of Novavax by 138.7% in the first quarter. BlackRock Inc. now owns 19,870 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 11,547 shares in the last quarter. Institutional investors own 76.06% of the company’s stock.
Novavax Company Profile
Novavax, Inc (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases.
Receive News & Stock Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related stocks with our FREE daily email newsletter.